Engineered anti-IL-2 antibodies
Described herein are engineered anti-IL-2 antibodies with modified amino acid sequences. The engineered antibodies would confer modified receptor binding specificity to an IL-2-anti-IL2 antibody complex, inhibiting the binding of IL-2 to CD25. The engineered anti-IL-2 antibodies would facilitate exp...
Saved in:
Main Authors | , , , , , , , , , , , , |
---|---|
Format | Patent |
Language | English |
Published |
26.12.2023
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Described herein are engineered anti-IL-2 antibodies with modified amino acid sequences. The engineered antibodies would confer modified receptor binding specificity to an IL-2-anti-IL2 antibody complex, inhibiting the binding of IL-2 to CD25. The engineered anti-IL-2 antibodies would facilitate expansion of subsets of effector immune cells and decrease undesirable effects caused by IL-2. Thus, the engineered anti-IL-2 antibodies would be useful in treating disease such as cancer and infection. |
---|---|
Bibliography: | Application Number: US202218055975 |